1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism

Journal of Endocrinological Investigation

Volumn 31, Issue 8, 2008, Pages 711-717

  St Arnaud, R ^a,b   Arabian, A ^a   Yu, V W C ^a   Akhouayri, O ^a   Knutson, J C ^c   Strugnell, S A ^c  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c Genzyme Corporation   (United States)

Author keywords

1,24(OH)2D2; 25 hydroxyvitamin D 1 hydroxylase; Bone; CYP27B1; PTH; SHPT

Indexed keywords

1ALPHA,24 DIHYDROXYVITAMIN D2; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; PARATHYROID HORMONE; UNCLASSIFIED DRUG; VITAMIN D; 1,24 DIHYDROXYVITAMIN D2; 1,24-DIHYDROXYVITAMIN D2; ERGOCALCIFEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE GROWTH; BONE STRUCTURE; CALCIUM BLOOD LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXPERIMENTAL MOUSE; GENE EXPRESSION; GROWTH INHIBITION; HYPERPARATHYROIDISM; MAINTENANCE DRUG DOSE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOMALACIA; PARATHYROID HORMONE BLOOD LEVEL; VITAMIN D DEFICIENCY; ANIMAL; BLOOD; BONE; CALCINOSIS; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; FEMUR; GENETICS; HISTOLOGY; HYPERCALCEMIA; PATHOLOGY; SECONDARY HYPERPARATHYROIDISM; TRANSGENIC MOUSE;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; BONE AND BONES; CALCINOSIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ERGOCALCIFEROLS; FEMUR; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; MICE; MICE, TRANSGENIC; PARATHYROID HORMONE; VITAMIN D DEFICIENCY;

EID: 56249093477     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346420     Document Type: Article

References (27)

1. St-Arnaud R, Dardenne O, Glorieux FH. Etiologie moléculaire des rachitismes vitamino-dépendents héréditaires. médecine/sciences 2001, 17: 1289-96.
2. Hruska KA. Renal osteodystrophy. Baillieres Clin Endocrinol Metab 1997, 11: 165-94.
3. Slatopolsky E, Gonzalez E, Martin K. Pathogenesis and treatment of renal osteodystrophy. Blood Purif 2003, 21: 318-26.
4. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342: 1478-83.
5. Dardenne O, Prud'homme J, Arabian A, Glorieux PH, St-Arnaud R. Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 2001, 142: 3135-41.
6. Panda DK, Miao D, Tremblay ML, et al. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci U S A 2001, 98: 7498-503.
7. Dardenne O, Prudhomme J, Hacking SA, Glorieux FH, St-Arnaud R. Rescue of the pseudo-vitamin D deficiency rickets phenotype of CYP27B1-deficient mice by treatment with 1,25-dihydroxyvitamin D3: biochemical, histomorphometric, and biomechanical analyses. J Bone Miner Res 2003, 18: 637-43.
8. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989, 321: 274-9.
9. Gallieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperperathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992, 42: 1191-8.
10. Slatopolsky E, Dusso A, Brown AJ. Control of uremic bone disease: role of vitamin D analogs. Kidney Int Suppl 2002: 143-8.
11. Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. J Am Soc Nephrol 2000, 11: 2088-94.
12. Frazão JM, Chesney RW, Coburn JW. Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group. Nephrol Dial Transplant 1998, 13 (Suppl 3): 68-72.
13. Frazão JM, Elangovan L, Maung HM, et al. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 2000, 36: 550-61.
14. Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998, 9: 1427-32.
15. Maung HM, Elangovan L, Frazão JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001, 37: 532-43.
16. Knutson JC, LeVan LW, Valliere CR, Bishop CW. Pharmacokinetics and systemic effect on calcium homeostasis of 1 alpha,24-dihydroxyvitamin D2 in rats. Comparison with 1 alpha,25-dihydroxyvitamin D2, calcitriol, and calcipotriol. Biochem Pharmacol 1997, 53: 829-37.
17. Strugnell S, Byford V, Makin HL, et al. 1 alpha,24(S)-dihydroxyvitamin D2: a biologically active product of 1 alpha-hydroxyvitamin D2 made in the human hepatoma, Hep3B. Biochem J 1995, 310 (Pt 1): 233-41.
18. Dickson GR. Methods of calcified tissue preparation. New York: Elsevier. 1984.
19. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2: 595-610.
20. Dardenne O, Prud'homme J, Hacking SA, Glorieux FH, St-Arnaud R. Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1 alpha-hydroxylase (CYP27B1). Bone 2003, 32: 332-40.
21. Ohyama Y, Noshiro M, Okuda K. Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24- hydroxylase. FEBS Lett 1991, 278: 195-8.
22. Hoenderop JG, van der Kemp AW, Urben CM, Strugnell SA, Bindels RJ. Effects of vitamin D compounds on renal and intestinal Ca2+ transport proteins in 25-hydroxyvitamin D3-1 alpha-hydroxylase knockout mice. Kidney Int 2004, 66: 1082-9.
23. Brown AJ, Ritter CS, Holliday LS, Knutson JC, Strugnell SA. Tissue distribution and activity studies of 1,24-dihydroxyvitamin D2, a metabolite of vitamin D2 with low calcemic activity in vivo. Biochem Pharmacol 2004, 68: 1289-96.
24. Tenenhouse HS, Gauthier C, Chau H, St-Arnaud R. 1alpha-Hydroxylase gene ablation and Pi supplementation inhibit renal calcification in mice homozygous for the disrupted Npt2a gene. Am J Physiol Renal Physiol 2004, 286: F675-81.
25. Omdahl JL, Bobrovnikova EA, Choe S, Dwivedi PP, May BK. Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway. Steroids 2001, 66: 381-9.
26. Zinser GM, Tribble E, Valrance M, et al. 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors. Anticancer Res 2005, 25: 235-41.
27. Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997, 30: 105-12.